EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a new beta adrenergic blocking agent carteolol based on metabolic responses in rats part 2 blockade by carteolol of the epinephrine and isoproterenol induced increases of tissue and blood cyclic amp in vivo


Biochemical Pharmacology 25(16): 1843-1849
Evaluation of a new beta adrenergic blocking agent carteolol based on metabolic responses in rats part 2 blockade by carteolol of the epinephrine and isoproterenol induced increases of tissue and blood cyclic amp in vivo
Epinephrine [i.p.] caused a slight but significant increase in cyclic[c]AMP in the liver and skeletal muscle in 5-10 min likewise, there was a significant increase in cAMP in the muscle and adipose tissue 5 min after the injection of isoproterenol, however no change was detected in the cardiac muscle. Pretreatment of rats with theophylline was so effective in enhancing responses of tissue cAMP as to make it possible to detect a 2- to 3-fold increase of cAMP even in the heart. The maximal increases in tissue cAMP induced by 500 .mu.g/kg of isoproterenol or epinephrine were blocked by carteolol, a new .beta.-adrenergic blocking agent, at doses of 10-100 .mu.g/kg, regardless of whether or not the rats had been treated with theophylline. Neither the increase of liver cAMP by glucagon nor the increase of adrenal cAMP by ACTH was affected by this agent. Blood cAMP rose sharply after isoproterenol, the maximal response attaining 20- to 30-fold of the preinjection level. Based on this tremendous increase of blood cAMP, the dose of isoproterenol and carteolol required for the half-saturation of the .beta.-adrenergic receptor was calculated as 20-30 and 0.5 .mu.g/kg of body wt, respectively. These values were in the same order as the respective values obtained from the response of carbohydrate and lipid metabolites in blood.


Accession: 005395339



Related references

Evaluation of a new beta-adrenergic blocking agent, carteolol, based on metabolic responses in rats-II. Blockade by carteolol of the epinephrine-and isoproterenol-induced increases of tissue and blood cyclic AMP in vivo. Biochemical Pharmacology 25(16): 1843-1849, 1976

Evaluation of a new beta adrenergic blocking agent carteolol based on metabolic responses in rats part 1 blockade in vivo of epinephrine and isoproterenol induced alterations of blood concentrations of carbohydrate and lipid intermediary metabolites. Biochemical Pharmacology 25(16): 1837-1842, 1976

Evaluation of a new beta-adrenergic blocking agent, carteolol, based on metabolic responses in rats-I. Blockade in vivo of epinephrine- and isoproterenol-induced alterations of blood concentrations of carbohydrate and lipid intermediary metabolites. Biochemical Pharmacology 25(16): 1836-1842, 1976

Metabolic fate of carteolol hydro chloride opc 1085 a new beta adrenergic blocking agent part 6 pharmaco kinetics of carteolol in rat dog rabbit and man. Folia Pharmacologica Japonica 73(2): 229-236, 1977

Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 73(2): 229-235, 1977

Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man. Arzneimittel-Forschung 27(12): 2380-2383, 1977

Metabolic fate of carteolol hydro chloride opc 1085 a new beta adrenergic blocking agent part 3 auto radiographic distribution studies in mice. Folia Pharmacologica Japonica 72(3): 341-350, 1976

Effect of carteolol a new beta adrenergic blocking agent on myo cardial metabolic response to coronary artery ligation in dogs. Japanese Journal of Pharmacology 27(3): 475-478, 1977

Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent. European Journal of Clinical Pharmacology 25(1): 95-101, 1983

Cardiac electrophysiologic action of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. Pacing and Clinical Electrophysiology 1(3): 292-305, 1978